GIIS113 – Resistencia Terapéutica y Metástasis

Perurena N#, Watanabe M, Schade AE, Brown W, Luo EY, Gardner A, Indeglia A, Yoshinaga A, Sahu R, Yang Y, Knott SRV, Cichowski K. EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer Research. 2026. doi: 10.1158/0008-5472.CAN-24-3113. #Co-corresponding author. FI-16,6

Loi P*, Schade AE*, Rodriguez CL, Krishnan A, Perurena N, Nguyen VTM, Xu Y, Watanabe M, Davis RA, Gardner A, Pilla NF, Mattioli K, Popow O, Gunduz N, Lannagan TRM, Fitzgerald S, Sicinska ET, Lin JR, Tan W, Brais LK, Haigis KM, Giannakis M, Ng K, Santagata S, Helin K, Sansom OJ, Cichowski K. Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers. Cancer Discovery. 2024. doi: 10.1158/2159-8290.CD-23-0866. *Co-first authors. FI-33,3

Schade AE, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Gardner A, Loi P, Xu Y, Nguyen V, Mastellone GM, Pilla NF, Watanabe M, Ota K, Davis RA, Mattioli K, Xiang D, Zoeller JL, Lin JR, Morganti S, Garrido-Castro AC, Tolaney S, Li Z, Barbie DA, Sorger PK, Helin K, Santagata S, Knott S, Cichowski K. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature. 2024. doi: 10.1038/s41586-024-08031-6. FI-50,5

Perurena N*, Situ L*, Cichowski K. Combinatorial strategies to target RAS-driven cancers. Nature Reviews Cancer. 2024. doi: 10.1038/s41568-024-00679-6. *Co-first authors. FI-66,8

Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Jänne PA, Cichowski K. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Journal of Clinical Investigation. 2023. doi: 10.1172/JCI167651. FI-13,6

Miller AL, Perurena N, Gardner A, Hinoue T, Loi P, Laird PW, Cichowski K. DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer Research. 2023. doi: 10.1158/0008-5472.CAN-22-0370. FI-16,6

Perurena N, Lock R, Davis RA, Raghavan S, Pilla NF, Ng R, Loi P, Guild CJ, Miller AL, Sicinska E, Cleary JM, Rubinson DA, Wolpin BM, Gray NS, Santagata S, Hahn WC, Morton JP, Sansom OJ, Aguirre AJ, Cichowski K. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Reports Medicine. 2023. doi: 10.1016/j.xcrm.2023.101007. FI-10,6